上皮性卵巢癌（EOC）是最致命的妇科癌症，因其治疗选择有限而带来重大临床挑战。叶酸受体α（FRα），由FOLR1基因编码，因其在EOC细胞中的广泛和高表达而成为一个具有吸引力的治疗靶点。近期的基础和转化研究已经探索了几种模式，如抗体药物结合物（ADC），单克隆抗体，小分子和叶酸药物结合物来利用FRα治疗EOC。在本综述中，我们总结了FRα的功能以及各种基于FRα的治疗方法的临床疗效。我们还重点介绍了第一个通过FDA批准用于治疗白金耐药性卵巢癌的FRα靶向ADC莫维西单抗索拉唑宾（MIRV）或埃拉赫（ImmunoGen）。我们还讨论了与MIRV治疗相关的眼部不良事件的潜在机制和管理方法。版权所有©2023年 脉、吴、杨、孙、刘、尹、蒋、李和李。

Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer, and presents a major clinical challenge due to limited treatment options. Folate receptor alpha (FRα), encoded by the FOLR1 gene, is an attractive therapeutically target due to its prevalent and high expression in EOC cells. Recent basic and translational studies have explored several modalities, such as antibody-drug conjugate (ADC), monoclonal antibodies, small molecules, and folate-drug conjugate, to exploit FRα for EOC treatment. In this review, we summarize the function of FRα, and clinical efficacies of various FRα-based therapeutics. We highlight mirvetuximab soravtansine (MIRV), or Elahere (ImmunoGen), the first FRα-targeting ADC approved by the FDA to treat platinum-resistant ovarian cancer. We discuss potential mechanisms and management of ocular adverse events associated with MIRV administration.Copyright © 2023 Mai, Wu, Yang, Sun, Liu, Yin, Jiang, Li and Li.